RPE65 gene therapy (Armata Pharmaceuticals)

N/A

Report date: 2023/10/26 16:14:22

Base Information

Drug NameRPE65 gene therapy (Armata Pharmaceuticals)
Drug Alias NametgAAG76tgAAG 76tgAAG-76rAAV2/2.hRPE65p.hRPE65AAV-RPE65 (AmpliPhi Biosciences)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionRPE65 gene transference
TargetsRetinoid isomerohydrolase
Therapy Area/IndicationsRetinal Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArmata Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity College London
Active IndicationsN/A
Inactive IndicationsRetinal Degeneration

Other Information

ATC CodeN/A
Related LinksN/A